The U.S. Food and Drug Administration (FDA) has halted sales after manufacturers failed to demonstrate long-term benefits of the devices.
@Hakinmhan_Shutterstock.com
The U.S. Food and Drug Administration (FDA) has ordered manufacturers of all remaining surgical mesh indicated for transvaginal repair of pelvic organ prolapse (POP) to stop selling and distributing the products in the United States immediately. The companies have 10 days to submit plans for withdrawing the mesh from the market.
Midurethral slings and mesh for sacrocolpopexy midurethral slings and mesh for sacrocolpopexy are not included in this recommendation. Sling devices and sacrocolpopexy mesh implants will remain on the US market.
“Fortunately, midurethral tapes and mesh used for abdominal sacral colpopexy were appropriately not targeted for elimination,” said Contemporary OB/GYN Editorial Board member John O. DeLancey, MD. “If the FDA had banned these appropriate uses of mesh that have proven to have excellent outcomes with minimal risk, patients would have been harmed.”
Over the past several years, the FDA has seen a significant increase in the number of reported adverse events associated with use of surgical mesh for transvaginal POP repair. In 2016, mesh devices were reclassified from class II (moderate risk) to class III (high risk) and manufacturers were required to submit premarket approval applications (PMA) in order to continue marketing their devices in the United States.
Boston Scientific filed two PMAs for its devices, Uphold LITE Vaginal Support System and Xenform Soft Tissue Repair System, while Coloplast filed one for its device, Restorelle DirectFix Anterior. In its review, the FDA found that both manufacturers failed to adequately assess the long-term safety of these devices and to demonstrate an acceptable long-term benefit compared to transvaginal surgical tissue repair without use of mesh.
In February 2019, the FDA organized an advisory panel to gather input from experts on how to evaluate the safety and effectiveness of the devices. The panel recommended that to support a favorable benefit-risk profile, surgical mesh’s effectiveness for transvaginal repair of POP should be superior to native tissue repair at 36 months and safety outcomes should be comparable for the two substances.
“There has been hope among some gynecologic surgeons that transvaginal mesh repairs for prolapse would improve on native tissue repair results with no increased risk of complications,” said Dr. De Lancey, who is Norman F. Miller Professor of Gynecology, Director, Pelvic Floor Research, and Group Director, Fellowship in Pelvic Medicine and Reconstructive Surgery at the University of Michigan Medical School. “An expert panel of surgeons affirmed that this standard should be used to judge the most recent post market surveillance data. The FDA determined that the data submitted by the companies in their required post-market analysis did not reach this standard. They have therefore required the manufacturers to discontinue these products.”
Impact of antiepileptic medications and sex hormones on maternal and child outcomes in epilepsy
May 16th 2024Paula Emanuela Voinescu, MD, PhD, director of the Women's Epilepsy Program at Brigham and Women's Hospital, talked about the influence of sex hormones on maternal outcomes in pregnant women with epilepsy treated with antiseizure medication.
Read More
PCOS and irregular cycles tied to cardiometabolic risks
May 15th 2024A comprehensive analysis reveals strong associations between polycystic ovary syndrome, irregular menstrual cycles, and increased risks of cardiometabolic conditions, underscoring the importance of proactive screening and intervention strategies.
Read More
Impact of primary care physicians on cervical cancer screening disparities
May 14th 2024A study highlights how having a primary care physician significantly increases the likelihood of cervical cancer screening among lesbian, gay, and bisexual cisgender women, addressing disparities exacerbated by systemic discrimination and healthcare access challenges.
Read More
Unlocking HPV prevention: Insights from 2022 data on vaccination trends
May 14th 2024Explore the latest findings revealing vaccination rates among children aged 9 to 17 years, uncovering demographic disparities and highlighting the crucial role of vaccination in combating human papillomavirus infections and related health risks.
Read More